Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Astellas is a Japanese drug company that discovers, develops, and sells prescription medicines, mainly for cancer, prostate and kidney problems, and transplants.
Astellas is a big Japanese maker of prescription medicines. It does not sell aspirin or cough syrup to shoppers. It sells serious drugs to hospitals and doctors, mostly in wealthy countries like the United States and Japan, and it makes most of its money in three areas: cancer treatments, prostate and kidney medicines, and drugs that keep transplanted organs from being rejected. It also runs a smaller business selling eye-care medicines, mainly in Japan.
The core of the company is cancer. One of its most important drugs, Xtandi, treats prostate cancer and earns billions of dollars a year, mostly in America. Astellas didn't invent Xtandi — it got the drug through a partnership with Pfizer and now books a big share of the sales, which is why the drug is the engine behind the company's profit. For prostate cancer it is a fierce three-way fight: besides Xtandi there is Johnson & Johnson's Erleada and Pfizer's Orgovyx, so the company is always hunting for the next big drug before old ones lose their patents. That hunt is expensive and unreliable, because new drugs mostly fail. Astellas spends heavily on research and buys promising companies and molecules to refill its pipeline. Its most famous recent bet is Izervay, an eye injection for a common cause of blindness in older people, which came with the acquisition of Iveric Bio. That deal turned into a nasty legal brawl: Novartis sued, claiming a former employee took trade secrets with him, and Astellas countersued. It is a reminder that drug profits come with patent cliffs and courtroom fights attached. The money machine is simple in principle, brutal in practice. A successful drug earns huge profits for a decade or two while it is protected by patents. When the patent runs out, cheap copies arrive and the revenue collapses almost overnight. Astellas is currently wrestling with that clock on some of the drugs that once drove its profits, which is why the pipeline matters so much. The company pays a steady dividend and has a strong balance sheet, so it can keep buying its way out of trouble — but investors are essentially betting on whether its next big drug arrives before the last one loses its crown.
Saved answer · last researched 23 Oct 2026
see a list of the most recent 300 searches below: